FORT LEE, N.J., May 16, 2011 /PRNewswire/ -- BAETA Corp. (OTCBB: BAEA) announced today that the NYU School of Medicine will conduct a clinical trial to measure the efficacy of the Company's "MyHealthTrends for Pain" handheld device during intra-operative, pre- and post-surgical periods. This trial will compare the current standard of pain care monitoring to Baeta's device which facilitates accurate data collection.
Michael Haile, MD, director of Clinical Research at NYU School of Medicine will oversee the initiative as the Principal Investigator. "We are interested in the practical application of a portable, handheld device for patients to quantify pain and the ability to translate this information into enhanced treatment regimens and outcomes relative to the current standard of pain care monitoring," said Dr. Haile.
The protocol has been reviewed and approved by NYU School of Medicine's Institutional Review Board (IRB).
"We look forward to the opportunity to determine if the standard of pain care monitoring can be advanced using this technology," said Dr. Alexander Gak, Chairman of Baeta Corp. "With limited tools to quantify pain, this is an important initiative for any individual suffering from acute or chronic pain," said Gak.
Upon conclusion of the clinical trial Baeta intends to apply for a CPT reimbursement code. "This is an important step for Baeta Corp's commercialization of its advanced patient care products," stated Len Pushkantser, CEO of Baeta Corp. Physicians, hospitals, and other health care providers use CPT codes to report medical services to private and public health insurance systems for purposes of reimbursement.
About Baeta Corp.
Baeta Corp. (OTC.BB: BAEA) is a technology-enabled he